Drugs / PremierMaxCB®-Platinum
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06415461 | May 2024 → Jan 2027 expected | arthritis, sacroiliac, bone pain, periodic | University of Florida | Active not recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PremierMaxCB-Platinum | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06415461 ↗ |
| Known as | CFL001 | “PremierMaxCB®-Platinum (CFL001);” NCT06415461 ↗ |